Cariprazine is a Small Molecule owned by Gedeon Richter, and is involved in 62 clinical trials, of which 54 were completed, 7 are ongoing, and 1 is planned.

Cariprazine is a dopamine D3 receptor-preferring, D3/D2 dopamine receptor partial agonist antipsychotic drug candidate. The drug candidate is partial agonists that matched precisely the projected properties of the agonist-antagonist bifunctional compounds. It affects the way the brain works by interfering with communication among the brain's nerves. The D2 receptor is coupled to inhibitory G-proteins, which dissociate from the receptor on agonist binding and inhibit secondary messenger signaling mechanisms. Cariprazine is a serotonin 5-HT1A receptors agonist and antagonist activity at serotonin 5-HT2A receptors.

The revenue for Cariprazine is expected to reach a total of $361m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cariprazine NPV Report.

Cariprazine is originated and owned by Gedeon Richter. Recordati and AbbVie are the other companies associated in development or marketing of Cariprazine.

Cariprazine Overview

Cariprazine (RGH -188, Vraylar, Reagila, Symvenu) is an atypical antipsychotic drug. It is formulated as hard gelatin capsules for oral route of administration. It is indicated for the treatment of manic or mixed episodes of bipolar 1 disorder and schizophrenia in adults. Vraylar is also indicated for the maintenance treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.

The drug candidate is also under development for the treatment of bipolar disorder, autism spectrum disorder and schizophrenia.

It was under development for the treatment of generalized anxiety disorder (GAD).

Recordati Overview

Recordati, a subsidiary of Fimei SpA, is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, central nervous system disorders, dermatology, musculoskeletal disorders and analgesia, and urology diseases. It also offers cosmetics, dietary supplements, pregnancy test products, over-the-counter (OTC) and non-prescription pharmaceuticals, anti-infectives and others. It manufactures pharmaceutical chemicals such as active pharmaceutical ingredients (APIs) and intermediates. The company sells its pharmaceuticals directly in the countries of its operations and through licensees in other places. Recordati is headquartered in Milan, Italy.

The company reported revenues of (Euro) EUR1,580.1 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. In FY2021, the company’s operating margin was 31%, compared to an operating margin of 32.4% in FY2020. In FY2021, the company recorded a net margin of 24.4%, compared to a net margin of 24.5% in FY2020. The company reported revenues of EUR485.1 million for the third quarter ended September 2022, an increase of 2.5% over the previous quarter.

Quick View – Cariprazine

Report Segments
  • Innovator (NME)
Drug Name
  • Cariprazine
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.